Zobrazeno 1 - 8 of 8 pro vyhledávání: '"A C M, van de Luijtgaarden"'
2
Gynaecomastie en mastodynie als gevolg van androgeendeprivatietherapie bij prostaatkanker
Autor: J. J. E. van Wijk-van Buuren, C. V. M. Vahedi Nikbakht-van de Sande, Margreet C. Kerkmeer, A. C. M. van de Luijtgaarden
Publikováno v: Tijdschrift voor Urologie. 12:2-6
SamenvattingIn het Reinier de Graaf Gasthuis maken mannen die androgeendeprivatietherapie krijgen vanwege prostaatkanker nauwelijks gebruik van behandelingen ter preventie van gynaecomastie en mastodynie. In een vragenlijstonderzoek is het optreden v
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1c3c83541e88d77d4f594e9a5f7afe1
https://doi.org/10.1007/s13629-021-00344-9
Zobrazit plný text záznamu
4
Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography
Autor: Martijn P. A. Starmans, Li Shen Ho, Fokko Smits, Nick Beije, Inge de Kruijff, Joep J. de Jong, Diederik M. Somford, Egbert R. Boevé, Ed te Slaa, Evelyne C. C. Cauberg, Sjoerd Klaver, Antoine G. van der Heijden, Carl J. Wijburg, Addy C. M. van de Luijtgaarden, Harm H. E. van Melick, Ella Cauffman, Peter de Vries, Rens Jacobs, Wiro J. Niessen, Jacob J. Visser, Stefan Klein, Joost L. Boormans, Astrid A. M. van der Veldt
Publikováno v: Journal of Personalized Medicine, 12
Journal of Personalized Medicine, 12, 5
Journal of Personalized Medicine
Journal of Personalized Medicine, 12(5):726. Multidisciplinary Digital Publishing Institute (MDPI)
Journal of Personalized Medicine; Volume 12; Issue 5; Pages: 726
Approximately 25% of the patients with muscle-invasive bladder cancer (MIBC) who are clinically node negative have occult lymph node metastases at radical cystectomy (RC) and pelvic lymph node dissection. The aim of this study was to evaluate preoper
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ba01999e50d754f948c0632eaa49c03
http://hdl.handle.net/2066/250949
Zobrazit plný text záznamu
5
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry
Autor: Diederik M. Somford, Reindert J.A. van Moorselaar, Carin A. Uyl-de Groot, Ronald de Wit, Laurent M.C.L. Fossion, Niven Mehra, Hans M. Westgeest, Addy C. M. van de Luijtgaarden, Juleon L.L.M. Coenen, N.I. Weijl, Maud M. Geenen, Winald R. Gerritsen, Agnes J. van de Wouw, A.C.M. van den Bergh, Mathijs P. Hendriks, Marco B. Polee, Alphonsus J. M. van den Eertwegh, Andre M. Bergman, Malou C.P. Kuppen, Inge M. van Oort, Daan ten Bokkel Huinink
Publikováno v: European urology oncology, 4(4), 618-627. De Tijdstroom/Elsevier
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV
Background: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5688ade1d20f2f2f131d73a057ff810
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028
Zobrazit plný text záznamu
6
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands
Autor: Haiko J. Bloemendal, Niven Mehra, Marco B. Polee, Joan van den Bosch, Alphonsus J. M. van den Eertwegh, Carin A. Uyl-de Groot, Daan ten Bokkel Huinink, H. P. (Pieter) van den Berg, Andre M. Bergman, Inge M. van Oort, Malou C.P. Kuppen, Addy C. M. van de Luijtgaarden, Laurent M.C.L. Fossion, Mathijs P. Hendriks, Juleon L.L.M. Coenen, Winald R. Gerritsen, Hans M. Westgeest, A.C.M. van den Bergh, Ronald de Wit, N.I. Weijl
Publikováno v: Clinical Genitourinary Cancer, 17, 5, pp. e946-e956
Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier
Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP
Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018
Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier
Clinical Genitourinary Cancer, 17, e946-e956
In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c55db3d2d7c2abd92a4b76a9b4278c5e
https://doi.org/10.1016/j.clgc.2019.05.018
Zobrazit plný text záznamu
7
High prevalence of late adverse events in malignant bone tumour survivors diagnosed at adult age
Autor: A C M, van de Luijtgaarden, L, Kapusta, L, Bellersen, J P M, Bokkerink, S E J, Kaal, Y M H, Versleijen-Jonkers, H W B, Schreuder, W T A, van der Graaf
Publikováno v: The Netherlands journal of medicine. 72(10)
Late treatment-related adverse events are particularly prevalent in survivors of childhood bone cancer because of the combination of cytotoxic drugs, major surgery and radiotherapy. Existing studies for late toxicity in survivors of Ewing's sarcoma (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6928b31b4b9b1a4df88a88d282d7c3fe
https://pubmed.ncbi.nlm.nih.gov/26219756
Zobrazit plný text záznamu
8
Targeted therapy for Ewing's sarcoma: significance of heterogeneity
Autor: A C M, Van De Luijtgaarden, W T A, Van Der Graaf, I, Otte-Höller, H W B, Schreuder, Y M H, Versleijen-Jonkers, P J, Slootweg
Publikováno v: Anticancer research. 30(9)
Survival in Ewing's sarcoma (ES) is limited. Experience with insulin-like growth factor targeting drugs, which require specific molecular tumour alterations, herald a major breakthrough. We screened for tumour heterogeneity within patients by DNA qua
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::df93e612a9f4b3a9e0cf6335246adc9e
https://pubmed.ncbi.nlm.nih.gov/20944159
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje